Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial
Dieci, M.V., Prat, A., Tagliafico, E., Paré, L., Ficarra, G., Bisagni, G., Piacentini, F., Generali, D.G., Conte, P., Guarneri, V.
Published in Annals of oncology (01.10.2016)
Published in Annals of oncology (01.10.2016)
Get full text
Journal Article
Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study
Conte, P., Frassoldati, A., Bisagni, G., Brandes, A.A., Donadio, M., Garrone, O., Piacentini, F., Cavanna, L., Giotta, F., Aieta, M., Gebbia, V., Molino, A., Musolino, A., Ferro, A., Maltoni, R., Danese, S., Zamagni, C., Rimanti, A., Cagossi, K., Russo, A., Pronzato, P., Giovanardi, F., Moretti, G., Lombardo, L., Schirone, A., Beano, A., Amaducci, L., Bajardi, E.A., Vicini, R., Balduzzi, S., D’Amico, R., Guarneri, V.
Published in Annals of oncology (01.12.2018)
Published in Annals of oncology (01.12.2018)
Get full text
Journal Article
De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study
Guarneri, V., Dieci, M.V., Bisagni, G., Frassoldati, A., Bianchi, G.V., De Salvo, G.L., Orvieto, E., Urso, L., Pascual, T., Paré, L., Galván, P., Ambroggi, M., Giorgi, C.A., Moretti, G., Griguolo, G., Vicini, R., Prat, A., Conte, P.F.
Published in Annals of oncology (01.06.2019)
Published in Annals of oncology (01.06.2019)
Get full text
Journal Article
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer
Dieci, M.V., Conte, P., Bisagni, G., Brandes, A.A., Frassoldati, A., Cavanna, L., Musolino, A., Giotta, F., Rimanti, A., Garrone, O., Bertone, E., Cagossi, K., Sarti, S., Ferro, A., Piacentini, F., Maiorana, A., Orvieto, E., Sanders, M., Miglietta, F., Balduzzi, S., D’Amico, R., Guarneri, V.
Published in Annals of oncology (01.03.2019)
Published in Annals of oncology (01.03.2019)
Get full text
Journal Article
Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2− breast cancer: results from two prospective trials
Dieci, M. V., Frassoldati, A., Generali, D., Bisagni, G., Piacentini, F., Cavanna, L., Cagossi, K., Puglisi, F., Michelotti, A., Berardi, R., Banna, G., Goubar, A., Ficarra, G., Griguolo, G., Conte, Pierfranco, Guarneri, V.
Published in Breast cancer research and treatment (01.06.2017)
Published in Breast cancer research and treatment (01.06.2017)
Get full text
Journal Article
Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer
Musolino, A, Naldi, N, Dieci, M V, Zanoni, D, Rimanti, A, Boggiani, D, Sgargi, P, Generali, D G, Piacentini, F, Ambroggi, M, Cagossi, K, Gianni, L, Sarti, S, Bisagni, G, Ardizzoni, A, Conte, P F, Guarneri, V
Published in The pharmacogenomics journal (01.10.2016)
Published in The pharmacogenomics journal (01.10.2016)
Get full text
Journal Article
Validation of the American Joint Committee on Cancer new prognostic stage groups for HER2-positive breast cancer patients treated with adjuvant chemotherapy and trastuzumab in the prospective ShortHER trial
Dieci, M.V., Bisagni, G., Brandes, A.A., Frassoldati, A., Donadio, M., Garrone, O., Piacentini, F., Balduzzi, S., Guarneri, V., Conte, P.F.
Published in Annals of oncology (01.05.2019)
Published in Annals of oncology (01.05.2019)
Get full text
Journal Article
Everolimus plus aromatase inhibitors vs aromatase inhibitors as maintenance therapy after first-line chemotherapy in HR+/HER2- metastatic breast cancer: Final results of the phase III randomized MAIN-A trial
Guarneri, V., Cinieri, S., Orlando, L., Bengala, C., Mariani, G., Bisagni, G., Frassoldati, A., Zamagni, C., De Salvo, G., Conte, P.F.
Published in Annals of oncology (01.05.2019)
Published in Annals of oncology (01.05.2019)
Get full text
Journal Article
The role of dose-dense (DD) adjuvant chemotherapy (CT) in HER2-positive (HER2+) early breast cancer (BC) patients (pts) before and after the introduction of trastuzumab (T): Exploratory analysis of the GIM2 trial
Lambertini, M., Bruzzone, M., Poggio, F., Conte, B., de Azambuja, E., Bisagni, G., De Laurentiis, M., de Placido, S., Cognetti, F., Del Mastro, L.
Published in Annals of oncology (01.05.2019)
Published in Annals of oncology (01.05.2019)
Get full text
Journal Article
Impact of 2013 ASCO/CAP guidelines on HER2 determination of invasive breast cancer: A single institution experience using frontline dual-color FISH
Ragazzi, M, Bisagni, A, Gasparini, E, Kuhn, E, Bassano, C, Tamagnini, I, Foroni, M, Bortesi, M, Falco, G, Ferrari, G, Braglia, L, Savoldi, L, Bologna, A, Di Cicilia, R, Bisagni, G, Gardini, G
Published in Breast (Edinburgh) (01.08.2017)
Published in Breast (Edinburgh) (01.08.2017)
Get full text
Journal Article
9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: Subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio
Conte, P.F., Guarneri, V., Bisagni, G., Piacentini, F., Brandes, A.A., Cavanna, L., Giotta, F., Aieta, M., Gebbia, V., Frassoldati, A., Musolino, A., Garrone, O., Taverniti, C., Rimanti, A., Sarti, S., Rubino, D., Bologna, A., Vicini, R., Balduzzi, S., D'Amico, R.
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
First line treatment with carboplatin-paclitaxel-bevacizumab in ovarian cancer: retrospective review of a single institute experience
Bologna, A., Garcia-Arias, A., Baldi, L., Berselli, A., Pagano, M., Zanelli, F., Bisagni, G., Gervasi, E., Stridi, G., Candida, B., Romagnani, A., Gnoni, R.
Published in Annals of oncology (01.10.2017)
Published in Annals of oncology (01.10.2017)
Get full text
Journal Article
A phase II study of pembrolizumab plus carboplatin in BRCA-related metastatic breast cancer (PEMBRACA)
Cortesi, L., Venturelli, M., Cortesi, G., Caggia, F., Toss, A., Barbieri, E., De Giorgi, U., Guarneri, V., Musolino, A., De Matteis, E., Zambelli, A., Bisagni, G., Dominici, M.
Published in ESMO open (01.04.2023)
Published in ESMO open (01.04.2023)
Get full text
Journal Article
Tumor-infiltrating lymphocytes (TILs) as an independent prognostic factor for early HER2+ breast cancer patients treated with adjuvant chemotherapy and trastuzumab in the randomized shortHER trial
Dieci, M.V., Conte, P.F., Bisagni, G., Brandes, A.A., Frassoldati, A., Cavanna, L., Musolino, A., Giotta, F., Rimanti, A., Garrone, O., Bertone, E., Cagossi, K., Sarti, S., Ferro, A., Omarini, C., Maiorana, A., Orvieto, E., Sanders, M., D'Amico, R., Guarneri, V.
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer
Gori, S., Montemurro, F., Spazzapan, S., Metro, G., Foglietta, J., Bisagni, G., Ferzi, A., Silva, R.R., Gamucci, T., Clavarezza, M., Stocchi, L., Fabi, A., Cognetti, F., Torrisi, E., Crivellari, D.
Published in Annals of oncology (01.06.2012)
Published in Annals of oncology (01.06.2012)
Get full text
Journal Article
Prognostic impact of interval breast cancer detection in women with pT1a N0M0 breast cancer with HER2-positive status: Results from a multicentre population-based cancer registry study
Musolino, A., Falcini, F., Sikokis, A., Boggiani, D., Rimanti, A., Pellegrino, B., Silini, E.M., Campanini, N., Barbieri, E., Zamagni, C., Degli Esposti, R., Cortesi, L., Bisagni, G., Cavanna, L., Frassoldati, A., Sgargi, P., Michiara, M.
Published in European journal of cancer (1990) (01.01.2018)
Published in European journal of cancer (1990) (01.01.2018)
Get full text
Journal Article
Efficacy of adjuvant chemotherapy schedules for breast cancer according to body mass index: results from the phase III GIM2 trial
Poggio, F., Blondeaux, E., Tagliamento, M., Perachino, M., Nardin, S., Conte, B., Giuliano, M., Arpino, G., De Laurentiis, M., Gravina, A., Bisagni, G., Rimanti, A., Turletti, A., Nisticò, C., Magnolfi, E., Gasparro, S., Fabi, A., Garrone, O., Alicicco, M.G., Urracci, Y., Poletti, P., Correale, P., Molinelli, C., Fozza, A., Puglisi, F., Colantuoni, G., Fregatti, P., Boni, L., Lambertini, M., Del Mastro, L.
Published in ESMO open (01.08.2024)
Published in ESMO open (01.08.2024)
Get full text
Journal Article
Nab-paclitaxel (Nab-P) in HER2-ve advanced breast cancer (ABC) patients (pts): focus on luminal cancers. Results from GIM13 - AMBRA study
Mustacchi, G, Cazzaniga, M, Giordano, M, Garrone, O, Donadio, M, Del Mastro, L, Livi, L, Natoli, C, Michelotti, A, Turletti, A, Riccardi, F, Marchetti, P, Montemurro, F, Romagnoli, E, De Placido, S, Biganzoli, L, Bisagni, G, Bria, E
Published in Annals of oncology (01.10.2017)
Published in Annals of oncology (01.10.2017)
Get full text
Journal Article
Final analysis of the phase III multicentric Italian study Short-HER: 9 weeks vs 1 year adjuvant trastuzumab for HER2+ early breast cancer
Conte, P., Conte, P., Bisagni, G., Frassoldati, A., Brandes, A., Cavanna, L., Giotta, F., Aieta, M., Gebbia, V., Musolino, A., Garrone, O., Donadio, M., Cavazzini, G., Turletti, A., Zamagni, C., Danese, S., Ferro, A., Piacentini, F., Balduzzi, S., D'Amico, R., Guarneri, V.
Published in Annals of oncology (01.10.2017)
Published in Annals of oncology (01.10.2017)
Get full text
Journal Article
Adjuvant Chemotherapy in Completely Resected Gastric Cancer: A Randomized Phase III Trial Conducted by GOIRC
Di Costanzo, Francesco, Gasperoni, Silvia, Manzione, Luigi, Bisagni, Giancarlo, Labianca, Roberto, Bravi, Stefano, Cortesi, Enrico, Carlini, Paolo, Bracci, Raffaella, Tomao, Silverio, Messerini, Luca, Arcangeli, Annarosa, Torri, Valter, Bilancia, Domenico, Floriani, Irene, Tonato, Maurizio
Published in JNCI : Journal of the National Cancer Institute (19.03.2008)
Published in JNCI : Journal of the National Cancer Institute (19.03.2008)
Get full text
Journal Article